<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577550</url>
  </required_header>
  <id_info>
    <org_study_id>1311.1</org_study_id>
    <secondary_id>2012-000081-37</secondary_id>
    <nct_id>NCT01577550</nct_id>
  </id_info>
  <brief_title>Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis</brief_title>
  <official_title>Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to
      severe psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with good and satisfactory assessment of global tolerability by investigator</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients without any symptoms at the drug administration site, at per local assessment of tolerability by investigator</measure>
    <time_frame>up to 1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant findings in vital signs</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in electrocardiogramm (ECG) results</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with significant changes from baseline laboratory measurements</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (absolute score)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Static Physicians Global Assessment (clear and almost clear)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (percentage change from baseline)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>i.v. BI 655066</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subject to receive a single i.v. dose of BI 655066</description>
  </arm_group>
  <arm_group>
    <arm_group_label>i.v. placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A subject to receive a single i.v. dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>s.c. BI 655066</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subject to receive a single s.c. dose of BI 655066</description>
  </arm_group>
  <arm_group>
    <arm_group_label>s.c. placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A subject to receive a single s.c. dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066 (very high i.v. dose)</intervention_name>
    <description>Single very high i.v. dose BI 655066</description>
    <arm_group_label>i.v. BI 655066</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, i.v.</intervention_name>
    <description>Single i.v. administration of placebo</description>
    <arm_group_label>i.v. placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066 (high s.c. dose)</intervention_name>
    <description>Single high s.c. dose BI 655066</description>
    <arm_group_label>s.c. BI 655066</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066 (low i.v. dose)</intervention_name>
    <description>Single low i.v. dose BI 655066</description>
    <arm_group_label>i.v. BI 655066</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066 (high medium i.v. dose)</intervention_name>
    <description>Single high medium i.v. dose BI 655066</description>
    <arm_group_label>i.v. BI 655066</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066 (very low i.v. dose)</intervention_name>
    <description>Single very low i.v. dose BI 655066</description>
    <arm_group_label>i.v. BI 655066</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066 (low s.c. dose)</intervention_name>
    <description>Single low s.c. dose BI 655066</description>
    <arm_group_label>s.c. BI 655066</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066 (high i.v. dose)</intervention_name>
    <description>Single high i.v. dose BI 655066</description>
    <arm_group_label>i.v. BI 655066</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, s.c.</intervention_name>
    <description>Single s.c. administration of placebo</description>
    <arm_group_label>s.c. placebo</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655066 (low medium i.v. dose)</intervention_name>
    <description>Single low medium i.v. dose BI 655066</description>
    <arm_group_label>i.v. BI 655066</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>risankizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female patients aged 18-75 years (inclusive)

          2. Chronic moderate to severe plaque psoriasis lasting =&gt;6 months with involvement of
             Body Surface Area (BSA) =&gt;10%, Psoriasis Area and Severity Index (PASI) =&gt;12 and
             Static Physician Global Assessment (sPGA) score of moderate and above

          3. Body Mass Index (BMI) =&gt;18.5 and &lt;40 kg/m2

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

          5. Female patients must not be of childbearing potential (i.e., must be postmenopausal or
             surgically sterilized) and must have a negative pregnancy test at screening.

        Exclusion criteria:

          1. Evidence of current or previous clinically significant disease, medical condition
             other than psoriasis, or finding of the medical examination (including vital signs and
             Electrocardiogram (ECG)), that in the opinion of the Investigator, would compromise
             the safety of the patient or the quality of the data. This criterion provides an
             opportunity for the investigator to exclude patients based on clinical judgment, even
             if other eligibility criteria are satisfied (Psoriatic arthritis is not considered an
             exclusion.)

          2. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders, diseases of the central nervous system (such as
             epilepsy) or psychiatric disorders or neurological disorders, chronic or relevant
             acute infections including hepatitis and tuberculosis (or a positive interferon-gamma
             release assay at screening) or history of orthostatic hypotension, fainting spells or
             blackouts, that in the investigator's judgement, could jeopardize the safe conduct of
             the study

          3. History of allergy/hypersensitivity to a systemically administered biologic agent or
             its excipients

          4. Use of biologic agents or psoralen and ultraviolet A (PUVA) within 12 weeks prior to
             Visit 2, ultraviolet B (UVB) phototherapy and oral anti-psoriatic medications within 4
             weeks prior to Visit 2, or topical anti-psoriasis medications (except emollients)
             within 2 weeks prior to Visit 2

          5. Use of ustekinumab within 24 weeks prior to Visit 2

          6. Had a prior treatment of psoriasis with biologics with inadequate clinical response to
             therapy as assessed by a dermatologist or the investigator

          7. Intake of restricted medications or drugs considered likely to interfere with the safe
             conduct of the study

          8. Use of drugs which might reasonably influence the results of the trial or that prolong
             the QT/QTc interval within 10 days prior to administration or during the trial

          9. Participation in another trial with an investigational drug within 4 weeks or 5
             half-lives (whichever is greater) preceding Visit 2

         10. History of alcohol abuse within last 12 months (intake of more than 30 g/day)

         11. History of drug abuse within last 12 months or positive drug screen at screening or
             Visit 2

         12. Any blood donation or significant blood loss within 4 weeks prior to Visit 2

         13. Unwilling or not capable to abstain from alcoholic beverages one day prior and two
             days after Visit 2

         14. Excessive physical activities (within 1 week prior to Visit 2)

         15. Any laboratory value at the screening visit outside the reference range that is of
             clinical relevance based on physician investigator judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc</last_name>
    <role>Study Chair</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1311.1.0007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.1.0008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.1.0003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.1.0005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.1.0006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.1.0004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.1.0002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.1.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1311.1.0009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABBV-066</keyword>
  <keyword>BI 655066</keyword>
  <keyword>risankizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

